Enlivex Therapeutics Ltd. (ENLV) Financials

ENLV Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 46.9 million 8.2 million
2023-06-30 53.0 million 8.7 million
2023-03-31 60.0 million 9.4 million
2022-12-31 67.6 million 10.8 million

ENLV Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -5.5 million 407000
2023-06-30 -7.1 million 511000
2023-03-31 -5.9 million 633000
2022-12-31 -7.4 million 757000

ENLV Net Income

No data available :(

ENLV Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 30.5 million - 4.5 million
2023-06-30 28.9 million - 4.4 million
2023-03-31 36.0 million - 4.7 million
2022-12-31 48.1 million - 653000

ENLV Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 18.6 million
2023-06-30 18.5 million
2023-03-31 18.5 million
2022-12-31 18.4 million

ENLV Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 29000 4.3 million 1.3 million -
2023-06-30 38000 5.0 million 1.6 million -
2023-03-31 162000 5.2 million 1.6 million -
2022-12-31 2.6 million 5.7 million 1.7 million -

ENLV Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - 214000
2023-06-30 - -
2023-03-31 - 209000
2022-12-31 - -

ENLV

Price: $1.58

52 week price:
1.15
4.59

Earnings Per Share: -1.47 USD

P/E Ratio: -2.18

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 21300

Market Capitalization: 24.2 million

Links: